CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. amendment No. 4 to CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • May 7th, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 11th day of April, 2024, by and among RIGEL PHARMACEUTICALS, INC., a Delaware corporation (“Rigel”), as a Borrower, MidCap FINANCIAL Trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
Amendment No. 2 to the License and Collaboration AgreementRigel Pharmaceuticals Inc • May 7th, 2024 • Pharmaceutical preparations
This Amendment No. 2 to the License and Collaboration Agreement by and between Rigel Pharmaceuticals, Inc. (“Rigel”), and Eli Lilly and Company (“Lilly”), is made and entered into as of the last signature to this Amendment No. 2 (the “Amendment No. 2 Effective Date”). Rigel and Lilly are each sometimes referred to individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT between BLUEPRINT...Asset Purchase Agreement • May 7th, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Asset Purchase Agreement is made and entered into as of the 22nd day of February, 2024, between Blueprint Medicines Corporation, a Delaware corporation (“Seller”), and Rigel Pharmaceuticals, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are individually referred to as a “Party” and collectively as the “Parties”.
